Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

July 31, 2027

Conditions

Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

BG1805

A single infusion of BG1805 Injection administered intravenously.

Trial Locations (3)

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

RECRUITING

ZhuJiang Hospital of Southern Medical University, Guangzhou

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY